Sema4C, a Transmembrane Semaphorin, Interacts with a Post-synaptic Density Protein, PSD-95*

Shinobu InagakiDagger §, Yoshiharu OhokaDagger , Hisako SugimotoDagger , Shiho FujiokaDagger , Mayumi AmazakiDagger , Hitomi KurinamiDagger ||, Nobuo MiyazakiDagger **, Masaya Tohyama||, and Tatsuo Furuyama||DaggerDagger

From the Dagger  Group of Neurobiology, School of Allied Health Sciences, Osaka University Faculty of Medicine, Yamadaoka 1-7, Suita-shi, Osaka, 565-0871, Japan and the Departments of || Neuroscience and Anatomy and ** Otorhinolaryngology, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita-shi, Osaka, 565-0871, Japan

Received for publication, October 4, 2000, and in revised form, December 26, 2000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Semaphorins are known to act as chemorepulsive molecules that guide axons during neural development. Sema4C, a group 4 semaphorin, is a transmembrane semaphorin of unknown function. The cytoplasmic domain of Sema4C contains a proline-rich region that may interact with some signaling proteins. In this study, we demonstrate that Sema4C is enriched in the adult mouse brain and associated with PSD-95 isoforms containing PDZ (PSD-95/DLG/ZO-1) domains, such as PSD-95/SAP90, PSD-93/chapsin110, and SAP97/DLG-1, which are concentrated in the post-synaptic density of the brain. In the neocortex, S4C is enriched in the synaptic vesicle fraction and Triton X-100 insoluble post-synaptic density fraction. Immunostaining for Sema4C overlaps that for PSD-95 in superficial layers I-IV of the neocortex. In neocortical culture, S4C is colocalized with PSD-95 in neurons, with a dot-like pattern along the neurites. Sema4C thus may function in the cortical neurons as a bi-directional transmembrane ligand through interacting with PSD-95.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Semaphorins are a large family of structurally distinct, secreted and transmembrane glycoproteins characterized by the presence of a conserved sema domain of about 500 amino acids (1, 2). Several secreted semaphorins (group 3 semaphorins in vertebrates), such as Sema3A, E, and F (3) induce the collapse of some populations of growth cones in cultured neurons and thus can function as inhibitory and repulsive cues in axonal guidance (1, 4-8). Evidence implicating secreted semaphorins in chemorepulsion came initially from the finding that chick Sema3A can cause the collapse of the chick dorsal root ganglion growth cone (4). Later studies have shown that Sema3A also acts as a chemorepellent for a variety of sensory and motor axons in mammals (5, 8). On the other hand, there is only limited evidence concerning the roles of transmembrane semaphorins in the nervous system. Of group 4 semaphorins, Sema4C (S4C, previously called M-SemaF) is especially expressed in neuronal tissues of embryos, suggesting some function of S4C in the neural tissues, such as directing axon pathfinding, axonal target selection, or synapse formation, although no evidence for such functions has been provided so far (9). Another group 4 semaphorin, Sema4D (previously called M-SemaG or hCD100; Refs. 10 and 11), regulates B lymphocyte proliferation and differentiation, and associates with a serine kinase through its cytoplasmic domain (11). Sema6B forms a complex with c-Src through a proline-rich intracellular domain (12). The cytoplasmic domain of S4C contains a proline-rich region that may interact with Src homology 3 (SH3)1 domains as well as cytoskeletal proteins, suggesting that the cytoplasmic domain of S4C may interact with some signaling-related proteins. To explore possible functions and the intracellular signaling of S4C, we investigated in which tissues and at which developmental stages S4C is expressed and then attempted to screen proteins that interact with S4C intracellularly. Based on yeast two-hybrid screening, we identified several PSD-95 isoforms as proteins interacting with S4C.

Recently, a number of proteins have been shown to contain PDZ domains, which were originally recognized as repeats of about 90 amino acids in PSD-95/SAP90 and named after three proteins containing such repeats, PSD-95, the Drosophila septate junction protein discs-large (DLG-A), and the epithelial tight junction protein zona occludens 1 (ZO-1) (13-18). PDZ proteins were originally thought to mediate the concentration of neurotransmitter receptors and ion channels at the synapses of neurons, as well as the asymmetric distribution of receptors in epithelial cells or their localization at tight junctions (19-21). Moreover, some of these PSD proteins also serve as scaffolds for the assembly of multiprotein signaling complexes at the membrane (13, 22-25). They mediate protein-protein interactions, generally recognizing short C-terminal motifs, originally described as the (T/S)XV motif (24). Interestingly, one such consensus PDZ binding motif, SSV, is also seen in the C terminus of S4C (9). In the present study we investigated whether PSD-95 interacts with S4C in the central nervous system.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antisera-- Antibodies to S4C were raised in rabbits against the product of pGEX5X1 S4Ccd, which is the C-terminal cytoplasmic domain of S4C. Mouse monoclonal antibodies to PSD-95 were purchased from Upstate Biotechnology (Lake Placid, NY) and Transduction Laboratories (Lexington, KY). Mouse monoclonal antibody to HA was obtained from Roche Molecular Biochemicals (Tokyo) and mouse monoclonal antibody to Myc (9E10) was purchased from American Type Culture Collection. Alkaline phosphatase-conjugated goat anti-rabbit IgG (Santa Cruz) or alkaline phosphatase-conjugated rabbit anti-mouse IgG (New England Bio Labs, Beverly, MA) was used as the second antibody for immunoblot detection.

Immunoblot Analysis-- Embryos and postnatal and adult ddY mice were purchased from SLC (Hamamatsu, Japan). Tissues were homogenized with 20 mM Hepes/NaOH, pH 7.4, 1 mM EDTA, 100 mM NaCl, and 1 mM phenylmethylsulfonyl fluoride (PMSF). The protein concentration was measured by the method of Coomassie protein assay reagent (Pierce). Twenty µg of each protein homogenate was fractionated by SDS-PAGE followed by immunoblotting with the indicated antibodies. Primary antisera to S4C, PSD-95, HA, and Myc were used at a 1: 2000 dilution. Immunoreactive proteins were visualized using CDP-Star detection reagent (Amersham Pharmacia Biotech) using the corresponding alkaline phosphatase-conjugated second antiserum.

Yeast Two-hybrid Screening-- The predicted cytoplasmic domain of the C-terminal amino acids of S4C (S4Ccd) (residues 663-834) was used to screen a rat brain cDNA library using the yeast two-hybrid technique following the instructions of the Matchmarker two-hybrid assay system (CLONTECH). The yeast two-hybrid libraries in pVP16 constructed from adult rat brain cDNA (26) were screened using pGBT9. The bait vector pGBT9 was constructed by subcloning the insert encoding the cytoplasmic domain of S4C. beta -Galactosidase (GAL) assays were performed using doubly transformed Y190 yeast cells with 5-bromo-4-chloro-3-indolyl beta -D-galactoside (X-gal) as previously described (26).

Constructions of Expression Vectors-- Prokaryote and eukaryote expression vectors were constructed in pGEX5X1 (Amersham Pharmacia Biotech), pGBT9 (CLONTECH), pVP16, pCMV, pCMV Myc, and pEF HA (Invitrogen) using standard molecular biology methods (27). The fusion protein with S4Ccd in pGBT9 and pGEX5X1 was prepared with a polymerase chain reaction fragment amplified from a plasmid containing mouse S4C cDNA (9) using reverse primer GCGTCGACTATACTGAAGACTCCTCTGG and forward primer GCGAATTCTGGGGCACGAGTGGCTC. The S4C mutant construct pGEX-S4C*cd (C-terminal three amino acids SSV (832) replaced with AAA) was prepared with a polymerase chain reaction fragment amplified from the S4C plasmid using reverse primer GCGTCGACTATGCTGCAGCCTCCTCTGGGTTGTTGGAGTC and forward primer GCGAATTCTGGGGCACGAGTGGCTC. pEF HA S4C, which contains the HA-tagged full-length coding region of S4C was used as a mammalian expression plasmid. pCMV Myc PSD-95-1 (the full-length sequence of rat PSD-95), pCMV PSD-95-2 (rat PSD-95 containing the first (PDZ1) and second PDZ (PDZ2) domains), pCMV PSD-95-3 (rat PSD95 containing the PDZ1, PDZ2, and PDZ3 domains), pCMV PSD-95-4 (rat PSD-95 lacking the PDZ3 domain), and pCMV Myc PSD-95-5 (rat PSD-95 containing PDZ3, SH3, and guanylate kinase (GK) domains) were prepared using polymerase chain reaction fragments which were inserted into the EcoRI/SalI sites of respective vectors. The prey vectors of pVP16 ratPSD95-8 (PDZ1+PDZ2+PDZ3), pVP16 SAP102 (PSDZ1+PDZ2+ PDZ3), pVP16 ratPSD-93 (PDZ1+PDZ2+PDZ3), pVP16 mouseZO-1 (PSDZ1+PD-Z2+PDZ3), and pVP16 Drosophila DLG-A (PDZ1+ PDZ2+PDZ3) (28) were used for the beta -galactosidase assays of yeast cotransformations with the bait vector pGBT9-S4Ccd.

In Vitro Binding-- Glutathione S-transferase (GST), GST-fused wild-type S4Ccd and GST-fused C-terminal mutant GST-S4C*cd proteins were expressed in Escherichia coli and purified as previously described (26). COS cells were transfected by the DEAE-dextran method with pCMV Myc PSD-95 (PSD-95-1), and various mutant plasmids of PSD-95 inserted into pCMV or pCMV Myc (PSD-95-2, -3, -4, and -5; see Fig. 4). The cells (in 10-cm plates) were homogenized in 0.3 ml of extract buffer (20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl, 1 mM PMSF, and 1% (w/v) Triton X-100) and centrifuged at 100,000 × g for 15 min. Five hundred µl of the supernatant (original) of GST, GST-S4Ccd, and GST-S4C*cd proteins were fixed on 20 µl of glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech). After the beads were washed with the extract buffer (flow through), proteins on the beads were subjected to the immunoblot analysis.

Subcellular Fractions-- Synapttosomal membrane and PSD (PSD1 and 2) fractions were prepared from the cerebral cortex of adult mice as previously described (26, 30) with minor modifications. Briefly, the cerebral cortexes from eight adult mice were homogenized in 36 ml of homogenization buffer (4 mM Hepes, pH 7.4, 1 mM EGTA, 0.32 M sucrose, and 1 mM PMSF) in a glass Teflon homogenizer. The homogenate was centrifuged at 1,000 × g for 10 min. The supernatant (S1) was collected and centrifuged at 9,200 × g for 15 min, and the resulting crude synaptosomal pellet (P2) was washed twice by resuspension in 24 ml of homogenization buffer and centrifugation at 10,200 × g for 15 min. The washed P2 pellet (P2') was lysed by osmotic shock with ice-cold distilled water, homogenized in a glass Teflon homogenizer, and centrifuged at 25,000 × g for 20 min to yield a supernatant (S3, crude synaptic vesicle fraction) and pellet (P3, lysed synaptosomal membrane fraction). The P3 fractions was resuspended in an appropriate volume of homogenization buffer and loaded onto a discontinuous sucrose density gradient (1.2 M sucrose, 0.8 M sucrose) and centrifuged at 150,000 × g for 1 h. Thereafter, the fraction was removed from the interface between 1.2 M sucrose and 0.8 M sucrose) and centrifuged at 150,000 × g for 30 min. The resulting pellet (synapttosomal membrane) was incubated for 15 min in ice-cold 0.5% Triton X-100 and then centrifuged at 32,000 g for 20 min to obtain the supernatant (S) the PSD pellet (PSD1). This PSD1 pellet was resuspended in an appropriate volume of homogenization buffer and incubated again for 15 min in ice-cold 0.5% Triton X-100 and then centrifuged at 201,800 × g for 20 min to obtain the supernatant (S) and the PSD pellet (PSD2). The S3 fraction was centrifuged at 165,000 × g for 2 h, and the resulting pellet (synaptic vesicle fraction) contained synaptic vesicle proteins. 10 µg of protein from each fraction was separated by SDS-PAGE, and immunoblot analysis was performed with the indicated antibodies.

Coimmunoprecipitation-- HEK 293 cells were cotransfected with pCMV Myc PSD-95-1 and pEF HA S4C or pEF HA S4C* by the calcium phosphate method as previously described (29). The supernatant from the cell extracts prepared by lysis with 20 mM Hepes/NaOH, pH 8.0, 150 mM NaCl, and 1% (w/v) Nonidet P-40, and 1 mM EDTA was diluted with two volumes of 20 mM Hepes/NaOH, pH 8.0, containing 150 mM NaCl and 1 mM EDTA and immunoprecipitated with anti-Myc or anti-HA antibody. The immunoprecipitates were separated by SDS-PAGE and analyzed by immunoblotting with either anti-S4C or anti-PSD-95 antibody.

The synaptosome fraction prepared from the cerebral cortexes of eight animals was homogenized in 16 ml of 20 mM Hepes/NaOH, pH 7.4, containing 6 M urea, 1% Triton X-100, and 1 mM PMSF and centrifuged at 100,000 g for 30 min. The supernatant was dialyzed against 3 liters of 20 mM Hepes/NaOH, pH 7.4 and 100 mM NaCl with one exchange of dialysis buffer and centrifuged at 100,000 × g for 30 min to remove the insoluble proteins. 4-ml aliquots of the supernatant (input) were incubated with the monoclonal anti-PSD95 antibody (Upstate Biotechnology) or the normal mouse serum for 3 h, and immune complexes were collected on 20 µl of protein A-Sepharose CL4B. After washing with 20 mM Hepes/NaOH, pH 7.4, 33 mM NaCl and 0.33% Triton X-100, the protein A beads were subjected to immunoblot analysis with anti-PSD-95 antibody (Transduction Laboratories) or the antibodies to S4C.

Immunohistochemistry-- HEK 293 cells transfected with pCMV Myc PSD-95 and pEF HA S4C were stained with the indirect immunofluorescence method. Cells grown on poly-L-lysine-coated coverslips were reacted with monoclonal antibody to Myc and polyclonal antibodies to S4C, nd then incubated with Cy2- or Cy3-labeled second antibodies to rabbit or mouse IgGs (Amersham Pharmacia Biotech). Cortical neurons cultured on the poly-L-lysine-coated coverslips (31) were also stained with the indirect immunofluorescence method using monoclonal antibody to PSD-95 and polyclonal antibody to S4C as described above. Immunofluorescence was visualized using a laser scanning confocal system (Radiance 2000, Bio-Rad). Immunohistochemistry was performed on adult mouse brain sections by the ABC method as previously described (32). Cryostat sections prepared from 4% paraformaldehyde-fixed animals were reacted with the antibodies to S4C either with or without antigen or with the antibody to PSD-95 and then incubated with biotinylated second antibodies to rabbit or mouse IgGs (Amersham Pharmacia Biotech). After reaction with avidin-biotin-horseradish peroxidase complex (Vecstatin ABC kit, Vector Laboratories, Burlingame CA), immunoreactivity was visualized with diaminobenzidine (Dotite, Japan).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Tissue and Developmental Stage-specific Expression of S4C Protein-- As semaphorins have primarily been found to act as axon guidance molecules during development of the nervous system, it is important to clarify in which tissues and at which developmental stages S4C is expressed. We analyzed the protein expression in homogenates from various tissues. A protein of about 100 kDa was detected in homogenates from brain by immunoblot analysis using the antiserum generated to the S4Ccd (Fig. 1). Examination of various tissues revealed that S4C protein was predominantly expressed in the brain, whereas little or none was detected in the other tissues, including heart, spleen, lung, liver, skeletal muscle, and kidney. Only traces of the protein were detected in placental tissue (Fig. 1A). Next we analyzed the protein expression in brain homogenates during at various developmental stages (Fig. 1B). S4C was apparent in the brain on embryonic day 14 (E14); thereafter, the protein level markedly increased by birth, and high levels of S4C were detected at birth and during the postnatal developmental stage at postnatal days 7 and 14. The expression was still very strong in the adult brain, suggesting that the S4C functions in the adult brain as well as in the developing brain.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 1.   Tissue distribution and developmentally regulated expression of S4C protein. A, immunoblot analysis of S4C in various tissues of mouse. The homogenates (20 µg of protein/lane) of various tissues were subjected to SDS-PAGE followed by immunoblot analysis using anti-S4C antibodies (1:2000). Lane 1, heart; lane 2, brain; lane 3, spleen; lane 4, lung; lane 5, liver; lane 6, muscle; lane 7, kidney; lane 8, placenta. B, immunoblot analysis of S4C in the brain during development. 20-µg protein aliquots of brain homogenates from mice at embryonic day 14 (E14), postnatal days 1 (P1), 7 (P7), and 14 (P14), and 8 weeks (Ad) were analyzed by immunoblotting with anti-S4C antibodies. Arrows in A and B indicate S4C protein of about 100 kDa.

S4Ccd Binds to PDZ-containing Protein, PSD-95 Family Molecules-- In an effort to study the functional mechanism of S4C, we searched for proteins that can bind to S4Ccd. We used the entire cytoplasmic domain of mouse S4C inserted into the GAL4 DNA-binding domain in pGBT9 vector (CLONTECH) as bait to screen an adult rat brain cDNA library in a yeast two-hybrid assay (26). We obtained 37 positive clones from 3 × 106 colonies. Eleven clones were false positives that encoded transcription factors. Sequence analysis revealed nine independent clones among 19 overlapping positive clones that represented three PSD-95 isoforms. Of these nine independent clones, four clones represented PSD-93/chapsin-110 (GenBankTM accession numbers; RNU49049, Ref. 33; RNU53368), three clones did PSD-95/SAP90 (GenBankTM accession numbers; M96853, Ref. 15; X66474, Ref. 17), and two clones represented SAP97/DLG-1 (HSU13897, Ref. 34; RNU14950, Ref. 35). Each open reading frame was in frame with the GAL4 activation domain. These clones representing PSD-95 isoforms necessarily contain the complete or partial sequence (longer than two-thirds) of the predicted PDZ1 domain and the complete sequence of PDZ2 but do not necessarily contain the following middle and C-terminal domains, PDZ3, SH3, and GK domains.

To test whether S4Ccd interacts with various MAGUK (PDZ containing membrane-associated guanylate kinase) members including ZO-1, a tight junction protein, and DLG-A, a Drosophila septate junction protein, as well as PSD-95 isoforms, the interactions were monitored as beta -galactosidase activity by using the yeast two-hybrid systems. Yeast cells were cotransformed with a bait vector pGBT9 S4Ccd and one of following prey vectors containing a MAGUK member such as pVP16 PSD-95/SAP90, SAP102, PSD-93/chapsin-110, ZO-1, and DLG-A. S4Ccd interact with the N terminus of PSD-95/SAP90, SAP102, and PSD-93/chapsin-110, which contain the three PDZ domains but lack the C-terminal SH3 or GK domains (Fig. 2). In contrast, we observed no interaction of S4Ccd proteins with the PDZ domains of a tight junction protein, ZO-1, or a Drosophila septate junction protein, DLG-A. Thus, there appears to be a specific interaction of the cytoplasmic domain of S4C with the PDZ domains of PSD-95 isoforms of synaptic proteins, such as PSD-95/SAP90, PSD-93/chapsin-110, and SAP102.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 2.   Yeast cells were cotransformed with a bait vector pGBT9 S4Ccd and a prey vector pVP16 containing the three PDZ domains of PSD-95/SAP90, SAP102, PSD-93/chapsin-110, ZO-1, or DLG-A. Cotransformants were selected on synthetic agar plates lacking leucine, tryptophan, and histidine. The interactions between S4Ccd, and the PDZ domains of each MAGUK member were observed by beta -galactosidase activity using colony lift beta -galactosidase filter assay according to the manufacturer's instructions.

In Vitro Binding Assay Showing the Interaction between the Cytoplasmic Tail of S4C and the PDZ Domains of PSD-95-- Because PSD-95 is the best characterized member of the above identified PSD-95 isoforms, PSD-95 was used for the following studies. The interactions observed above were next explored via "pull-down" assays in which GST fusion proteins bearing wild type (GST-S4Ccd) or C-terminal mutated S4Ccd (GST-S4C*cd) were used to pull down the full-length PSD-95 proteins and various truncated forms of PSD-95 expressed in mammalian cells. Cell extracts from COS cells transfected with pCMV Myc-PSD-95 were incubated with immobilized GST-S4Ccd or GST-S4C*cd proteins. Immunoblot analysis showed no interaction of PSD-95 with GST but showed a strong interaction of PSD-95 with GST- S4Ccd (Fig. 3). Substitution of three amino acid residues with three alanines at the C terminus of S4Ccd (GST-S4C*cd) abolished the interaction with PSD-95. These in vitro binding experiments suggested that the cytoplasmic tail of S4C interacts with PSD-95. Next, we investigated which region of PSD-95 interacts with S4C. Cell extracts from COS cells transiently expressing wild type (PSD95-1) and mutated PSD-95 (PSD95-2 ~ 5)(Fig. 4, A and B) were incubated with immobilized GST-S4Ccd proteins (Fig. 4C). Wild type PSD-95 and three truncated forms, PSD-95-2 (PDZ1 + PDZ2), PSD-95-3 (PDZ1 + PDZ2 + PDZ3), and PSD-95-4 (PDZ1 + PDZ2 + SH3 + GK) bound to GST-S4Ccd, whereas removal of PDZ1 and PDZ2 from PSD-95 (PSD-95-5) almost completely abolished the association with GST-S4Ccd (Fig. 4C). These in vitro binding experiments suggest that the PDZ1 and PDZ2 domains of PSD-95 interact with the C terminus of S4C.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 3.   In vitro analysis showing the interaction of PSD-95 with the C terminus of S4C. Three amino acids of the C terminus of S4C, SSV, were substituted by three alanines (S4C*cd). The extracts from COS cells transfected with pCMV Myc PSD-95 were incubated with GST and GST fusion proteins immobilized on glutathione-Sepharose 4B beads. The original cell extracts (OR), flow through fraction (FT), and beads pellet (PT) were subjected to SDS-PAGE followed by immunoblot analysis with anti-Myc antibody.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 4.   In vitro analysis showing the interaction of PDZ domains of PSD-95 with S4C. A, schematic representation of pCMV constructs of wild type (1) and various deletion mutants of PSD-95 (2-5). B, immunoblotting (IB) with anti-PSD-95 or anti-Myc antibodies. Wild type (1) and various mutants of PSD-95 (2-5) were expressed in cells and present in the respective cell lysates (arrows). Many bands of smaller in size than the bands indicated by arrows appears to be degraded PSD-95 proteins. C, interaction with the S4Ccd immobilized on glutathione beads. GST-fused S4Ccd incubated with MycPSD95-1 (lane 1), PSD95-2 (lane 2), PSD95-3 (lane 3), PSD95-4 (lane 4), or MycPSD95-5 (lane 5), was immunoblotted with anti-PSD-95 (lanes 1-4) or anti-Myc antibodies (lane 5). Wild type (lane 1) and deletion mutants of PSD95-2, 3, 4 (lanes 2-4) bound to S4Ccd (indicated by arrows), but mutant PSD-95-5 lacking PDZ1 and PDZ2 (indicated by an arrow) did not (lane 5). Degraded proteins bound to S4C are also observed in lanes 1-4.

Interaction of PSD-95 and S4C in Mammalian Cells-- To confirm the interaction of PSD-95 and full-length S4C in a cellular environment, HEK293cells were cotransfected with pCMV Myc PSD-95 and pEF HA S4C wild type or pEF HA S4C*mutant. The cell lysate was immunoprecipitated with anti-HA or anti-Myc antibodies on protein A beads and analyzed by immunoblotting with anti-S4C antibody (Fig. 5, upper right panel) or with anti-PSD-95 antibody (Fig. 5, lower right panel). Anti-Myc antibody precipitated the Myc-PSD-95 protein from transfected cells, and Myc-PSD-95 protein coimmunoprecipitated with HA-S4C protein and vice versa. HA-S4C protein precipitated as a complex containing Myc-PSD-95 protein, whereas HA-S4C* mutant protein failed to precipitate Myc-PSD-95 protein.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 5.   Interaction of S4C with PSD-95 in mammalian cells. Coimmunoprecipitation (IP) of PSD-95 with S4C. Myc-tagged PSD-95 with full-length HA-tagged S4C or its C-terminal mutant S4C* were expressed in HEK 293 cells, and cell lysates were prepared and immunoprecipitated with anti-Myc antibody or anti-HA antibody (right panels). Anti-S4C or anti-PSD-95 antibody was used to detect S4C or PSD-95 protein. Myc PSD-95 was not coimmunoprecipitated with C-terminal mutant S4C* but was with wild type S4C, and vice versa. HA-S4C but not with HA-S4C* mutant was coimmunoprecipitaed with PSD-95.

Subcellular Distribution-- PSD-95 is a synapse-associated protein, enriched in PSD fractions (15) (Fig. 6). If S4C interacts with PSD-95 in the brain, S4C should be enriched in PSD fractions. We explored whether S4C is concentrated in the synaptosome and PSD fractions by immunoblotting analysis using antiserum to S4C (Fig. 6). S4C was enriched in the crude synaptosomal pellet (P2) fraction as compared with the homogenate or cytosolic synaptosomal (S2) fraction. The subfractionation of P2 crude synaptosomal pellet into the synaptic vesicle fraction, the lysed crude synaptosomal membrane (P3) fraction, the synaptosomal membrane fraction, and Triton X-100 insoluble PSD1and 2 fractions showed that S4C was most enriched in the synaptic vesicle and PSD fractions (PSD1 and PSD2), where PSD-95 was also most enriched (Fig. 6). These results suggest that S4C is associated with both pre- and post-synaptic components. S4C enriched in the PSD fraction most likely associates with PSD-95.


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 6.   S4C and PSD-95 are present in the PSD fraction of the cerebral cortex. Various subcellular fractions (10 µg of protein/lane) were analyzed by immunoblotting with anti-S4C antibody (upper panel) or anti-PSD-95 antibody (lower panel) by subsequent reprobing. Arrowheads indicate either S4C or PSD-95 proteins. The procedures and abbreviations are as described under "Experimental Procedures" for subcellular fractions. HO, homogenate; SV, synaptic vesicle.

Interaction of S4C and PSD-95 in the Brain-- To examine whether endogenous S4C interacts with endogenous PSD-95, brain cytosol was immunoprecipitated with an antiserum to PSD-95 (Upstate Biotechnology) and probed with antibodies to S4C by immunoblot analysis. Because PSD-95 and S4C proteins are concentrated in the Triton X-100-insoluble pellet (PSD1 and PSD2) of the synaptosome, urea-containing buffer was used to extract these proteins from the crude synaptosomal pellet fraction (P2), and the extract was immunoprecipitated with normal mouse serum or antibody to PSD-95. The immunoprecipitates were analyzed by immunoblotting with antibody to PSD-95 (Transduction Laboratories) to check the specificity of this antibody (Fig. 7A, left panel) and with antibody to S4C (Fig. 7A, right panel). PSD-95 protein coprecipitated with S4C in the P2 fraction from the cerebral cortex, suggesting the interaction of PSD-95 and S4C in the central nervous system. Immunohistochemical experiments showed that there is partial overlap of S4C and PSD-95 in the superficial layers of the cerebral cortex of the adult mouse (Fig. 7B). S4C was localized to the superficial layers of layers I-IV, whereas PSD-95 was extensively distributed throughout the cortical layers. In the parietal cortex, S4C was detected in the barrel fields, which receive projections especially from cutaneous mechanoreceptors of the mystacial vibrissae (Fig. 7B). This pattern was similar to that of PSD-95. This is the first report showing immunohistochemical localization for S4C so far. In primary cultures of neocortical neurons, immunostaining for S4C was found in the neurites of cortical neurons with a dot-like pattern and was colocalized with PSD-95 (Fig. 7C). These results suggest that S4C enriched in the PSD is related to the modulation of neocortical neurons that receive thalamocortical sensory projections.


View larger version (67K):
[in this window]
[in a new window]
 
Fig. 7.   Interaction of PSD-95 with S4C in the adult cerebral cortex. A, coimmunoprecipitation (ip) of PSD-95 and S4C in the cerebral cortex. Urea/detergent extracts of crude cerebral cortical synaptosomes (input) were immunoprecipitated with normal mouse serum or monoclonal anti-PSD-95 antibody (Upstate Biotechnology) with protein A-Sepharose beads. After washing, proteins on the beads were subjected to SDS-PAGE (10.5% polyacrylamide gel) followed by immunoblot analysis with monoclonal anti-PSD-95 antibody (Transduction Laboratories) (left panel) or anti-S4C polyclonal antibody (right panel). B, immunohistochemical distribution of PSD-95 and S4C in the parietal cortex. S4C is localized in the superficial layers (I-IV) of the cortex, and PSD-95 is abundant throughout the cortical layers. The immunostaining pattern of S4C and PSD-95 overlapped in the superficial layers I-IV of the neocortex. S4C is also expressed in the barrel fields with similar pattern to PSD-95. The right panel shows the corresponding cortical regions stained with cresyl violet. Scale bar, 100 µm. C, colocalizaton of S4C and PSD-95 in primary cultured cortical neurons by immunofluorescent histochemistry. Dissociated E16 cortical cells were cultured for 9 days and stained with polyclonal anti-S4C antibodies and monoclonal anti-PSD-95 antibody. The left panel shows the immunofluorescence for S4C, the middle panel shows that for PSD95, and the right panel shows that for both antigens. S4C (red) and PSD-95 (green) are observed on neurites with a dot-like pattern (shown in higher magnification of images demarcated in the upper left corner of each panel) as well as neuronal cell bodies (asterisks). Scale bars, 50 µm.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The present study shows that S4C is enriched in the adult brain as well as postnatal developing brain, whereas its level is very low in other tissues, such as heart, lung, liver, kidney, and spleen. Brain-specific expression of S4C protein is almost parallel with that of S4C mRNA (36). Developmentally, expression of S4C mRNA (36) slightly precedes that of the protein. S4C mRNA and protein can be detected at embryonic stage, and they are abundant in postnatal and adult brains. S4C is a component of the PSD and interacts with PSD-95, which is a scaffold protein, that interacts with excitatory neurotransmitter receptors, ion channels, synaptic adhesion, and signaling proteins and that is important molecule coupling the NMDA receptor to signaling pathways that control bi-directional synaptic plasticity and learning (14, 18, 19, 22, 23, 26, 33). Importantly, we showed that S4C is colocalized with PSD-95 in cerebral cortical neurons.

The PDZ Domains at the N-terminal of PSD-95 Are Responsible for the Interaction with the Cytoplasmic Tail of S4C-- In vitro affinity binding experiments revealed the interaction of PSD-95 with the cytoplasmic domain of S4C expressed in mammalian cells. In vitro binding experiments using mutated PSD-95 and S4C showed that three amino acids of the C terminus of S4C are necessary for binding to the first and second PDZ domains of PSD-95. PSD-95 and its isoforms including PSD-93/Chapsyn-110 and SAP97/DLG-1 are prominent brain-specific proteins that are enriched in the PSD fraction, and one of the components of a dense thickening of postsynaptic submembranous cytoskelton observed in electron microscopy. These proteins have three N-terminal PDZ domains, a SH3 domain, and a guanylate kinase domain in their C termini. PSD-95 isoforms interact with NMDA receptors and Shaker-type potassium channels through the first and second PDZ domains, and brain nitric-oxide synthase through the second PDZ domain to induce the clustering of these molecules at the PSD (18, 19, 33-35, 37). Through the third PDZ domain, PSD-95 also interacts with various signaling and adhesion molecules, such as a synaptic adhesion molecule, neuroligin (28), a microtuble-associated molecule, CRIPT (38), and signaling molecules such as SynGAP (39), a Ras-GTPase activating protein at excitatory synapses that stimulates the GTPase activity of Ras and thus may negatively regulate Ras activity, Citron (40), a target for the activated form of the small GTP-binding protein Rho, and Fyn (41), a member of the Src-family protein-tyrosine kinases implicated in learning and memory that involves NMDA receptor function. A number of PSD-95-binding proteins, including S4C, may be related to each other in their signaling because they are in close proximity to each other because of interacting with PSD-95, although there have been no studies showing direct interactions among PSD-95-binding proteins.

PSD-95 and S4C May Be Involved in Bi-directional Synaptic Plasticity and Learning-- In mutant mice lacking PSD-95, the frequency function of NMDA-dependent long term potentiation and long term depression is shifted to produce strikingly enhanced long term potentiation at different frequencies of synaptic stimulation (42). This frequency shift is accompanied by severely impaired spatial learning. However, synaptic NMDA receptor currents, subunit expression, localization, and synaptic morphology are all unaffected in the mutant mice. PSD-95 thus appears to be important in coupling the NMDA receptor to signaling pathways that control bi-directional synaptic plasticity and learning. Several synaptic adhesion molecules such as neuroligins and cadherins are thought to be involved in such synaptogenesis and synaptic plasticity (43, 44). Neuroligins are a family of synaptic cell adhesion molecules that interact with beta -neurexins and form heterophilic intercellular junctions (45). Neurexins are primarily known as receptors for alpha -laterotoxin, which binds to presynaptic nerve terminals and triggers massive neurotransmitter release. Among the neurexins, beta -neurexin, an alternatively spliced form, functions as a receptor for neuroligin and most likely is involved in bi-directional signaling at excitable synapses. The cytoplasmic domain of neuroligins binds to the third PDZ domain of PSD-95, whereas S4C, NMDA2 receptors, and Shaker-type potassium channels interact with the first and second PDZ domains. S4C may regulate NMDA signaling by competing with NMDA receptors or potassium channels for binding the first and second PDZ domains of PSD-95.

Interaction of S4C with Other Proteins-- A recent study (36) showed the interaction of S4C with GIPC (a protein interacting with the RGS protein GAIP), which has a central PDZ domain and a C-terminal acyl-carrier protein domain. The central PDZ domain of GIPC interacts with GAIP, a GTPase-activating protein for Galpha i subunits localized on clathrin-coated vesicles. The PDZ domain of GIPC interacts with the C terminus of S4C and neuropilin 1, which is a receptor for secreted group 3 semaphorin, as well as the C terminus of GAIP (36, 46, 47). Because GAIP expression is very low in the brain, GIPC interacts with S4C and neuropilin 1 in the brain but not with GAIP. GIPC mRNA and protein are widely expressed in various tissues such as the pancreas, skeletal muscle, kidney, placenta, lung, and liver, as well as the brain (46, 47). In contrast, S4C expression is predominantly localized in brain tissues, suggesting that S4C most likely functions mainly in brain tissues. GIPC may compete with PSD-95 for binding S4C when GIPC is present at the PSD. However, Wang et al. (36) showed that GIPC is localized in the cell soma of neocortical neurons with large punctual features but not in neurites, which is similar to the findings in transfected HeLa cells (46). Therefore, S4C most likely interacts with PSD-95 at the PSD of the excitable synapses in the central nervous system, whereas S4C interacts with GIPC mainly in the cell soma of neurons. These results suggest that S4C plays distinct roles depending on its subcellular localization in neurons.

Possible Receptor for S4C-- A recent study showed that Sema4D binds to mammalian cells transfected with plexin B1 (48), suggesting that plexin is a candidate for a counterpart receptor for S4C. Plexins (48-51) encode large transmembrane proteins whose cysteine-rich extracellular domains share regions of homology with the scatter factor receptors encoded by the Met gene family (Met-related sequences). The extracellular domain also contains sema domains of about ~500 amino acids. Semaphorins contain cysteine-rich Met-related sequences and sema domains. It has been suggested that these families were derived from a common evolutionary ancestor with homophilic binding properties (52). The cytoplasmic domain of plexins (~600 amino acids) is highly conserved but shares no homologous regions with the Met tyrosine kinase domain nor with any other known protein. S4C-plexin signaling may be involved in bi-directional NMDA or neuroligin-neurexin intercellular signaling, and this can be tested by examining whether S4C is linked to the NMDA receptor or neuroligin at synapses through PSD-95.

    ACKNOWLEDGEMENTS

We thank Dr. Stanley Hollenberg for the gift of vectors for yeast two-hybrid assays, Drs. Yutaka Hata and Yoshimi Takai for the gift of vectors for PSD-95/SAP90, PSD-93, and ZO-1, and cDNA libraries for yeast two-hybrid screening.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom all correspondence should be addressed. Tel.: 81-6-6879-2581; Fax: 81-6-6879-2629; E-mail: inagaki@sahs.med.osaka-u.ac.jp.

Present address: Lab. for Motor System Neurodegeneraion, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan.

Dagger Dagger Present address: Dept. of Molecular Genetic Research, National Institute for Longevity Sciences, Morioka-cho, Ohbu-shi 474, Japan.

Published, JBC Papers in Press, December 27, 2000, DOI 10.1074/jbc.M009051200

    ABBREVIATIONS

The abbreviations used are: SH, Src homology; PMSF, phenylmethylsulfonyl fluoride; PAGE, polyacrylamide gel electrophoresis; HA, hemagglutinin; GST, glutathione S-transferase; PSD, post-synaptic density; NMDA, N-methyl-D-aspartate; MAGUK, membrane-associated guanylate kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Tessier-Lavigne, M., and Goodman, C. S. (1996) Science 274, 1123-1133[Abstract/Free Full Text]
2. Kolodkin, A. L., Matthes, D. J., and Goodman, C. S. (1993) Cell 75, 1389-1399[Medline] [Order article via Infotrieve]
3. Semaphorin Nomenclature Committee. (1999) Cell 97, 551-552[Medline] [Order article via Infotrieve]
4. Luo, Y., Raible, D., and Raper, J. A. (1993) Cell 75, 217-227[Medline] [Order article via Infotrieve]
5. Adams, R. H., Lohrum, M., Klostermann, A., Betz, H., and Puschel, A. W. (1997) EMBO J. 16, 6077-6086[Abstract/Free Full Text]
6. Miyazaki, N., Furuyama, T., Sakai, T., Fujioka, S., Mori, T., Ohoka, Y., Takeda, N., Kubo, T., and Inagaki, S. (1999) Neuroscience 93, 401-408[CrossRef][Medline] [Order article via Infotrieve]
7. Miyazaki, N., Furuyama, T., Amasaki, M., Sugimoto, H., Sakai, T., Takeda, N., Kubo, T., and Inagaki, S. (1999) Neurosci. Res. 33, 269-274[CrossRef][Medline] [Order article via Infotrieve]
8. Kobayashi, H., Koppel, A. M., Luo, Y., and Raper, J. A. (1997) J. Neurosci. 17, 8339-8352[Abstract/Free Full Text]
9. Inagaki, S., Furuyama, T., and Iwahashi, Y. (1995) FEBS Lett. 370, 269-272[CrossRef][Medline] [Order article via Infotrieve]
10. Furuyama, T., Inagaki, S., Kosugi, A., Noda, S., Saitoh, S., Ogata, M., Iwahashi, Y., Miyazaki, N., Hamaoka, T., and Tohyama, M. (1996) J. Biol. Chem. 271, 33376-33381[Abstract/Free Full Text]
11. Elhabazi, A., Lang, V., Herold, C., Freeman, G. J., Bensussan, A., Boumsell, L., and Bismuth, G. (1997) J. Biol. Chem. 272, 23515-23520[Abstract/Free Full Text]
12. Eckhardt, F., Behar, O., Calautti, E., Yonezawa, K., Nishimoto, I., and Fishman, M. C. (1997) Mol. Cell. Neurosci. 9, 409-419[CrossRef]
13. Pawson, T., and Scott, J. D. (1997) Science 278, 2075-2080[Abstract/Free Full Text]
14. Pongting, C. P., Phillips, C., Davies, K. E., and Blake, D. J. (1997) BioEssays 19, 469-479[Medline] [Order article via Infotrieve]
15. Cho, K. O., Hunt, C. A., and Kennedy, M. B. (1995) Neuron 9, 929-942
16. Woods, D. F., and Bryant, P. J. (1993) Mech. Dev. 44, 85-89[CrossRef][Medline] [Order article via Infotrieve]
17. Kistner, U., Wenzel, B. M., Veh, R. W., Cases-Langhoff, C., Garner, A. M., Appeltauer, U., Voss, B., Gundelfinger, E. D., and Garner, C. C. (1993) J. Biol. Chem. 268, 4580-4583[Abstract/Free Full Text]
18. Kornau, H. C., Seeburg, P. H., and Kennedy, M. B. (1997) Curr. Opin. Neurobiol. 7, 368-373[CrossRef][Medline] [Order article via Infotrieve]
19. Sheng, M. (1996) Neuron. 17, 575-578[Medline] [Order article via Infotrieve]
20. Kim, S. K. (1997) Curr. Opin. Cell Biol. 9, 853-859[CrossRef][Medline] [Order article via Infotrieve]
21. Bredt, D. S. (1998) Cell 94, 691-694[Medline] [Order article via Infotrieve]
22. Ranganathan, R., and Ross, E. M. (1997) Curr. Biol. 7, R770-R773[Medline] [Order article via Infotrieve]
23. Tsunoda, S., Sierralta, J., Sun, Y., Bodner, R., Suzuki, E., Becker, A., Socolich, M., and Zuker, C. S. (1997) Nature 388, 243-249[CrossRef][Medline] [Order article via Infotrieve]
24. Songyang, Z., Fanning, A. S., Fu, C., Xu, J., Marfatia, S. M., Chishti, A. H., Crompton, A., Chan, A. C., Anderson, J. M., and Cantley, L. C. (1997) Science 275, 73-77[Abstract/Free Full Text]
25. Fanning, A. S., and Anderson, J. M. (1999) Curr. Opin. Cell Biol. 11, 432-439[CrossRef][Medline] [Order article via Infotrieve]
26. Hata, Y., Butz, S., and Sudhof, T. C. (1996) J. Neurosci. 16, 2488-2494[Abstract]
27. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , 2nd Ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
28. Irie, M., Hata, Y., Takeuchi, M., Ichtchenko, K., Toyoda, A., Hirao, K., Takai, Y., Rosahl, T. W., and Sudhof, T. C. (1997) Science 277, 1511-1515[Abstract/Free Full Text]
29. Sakai, T., Furuyama, T., Ohoka, Y., Miyazaki, N., Fujioka, S., Sugimoto, H., Amasaki, M., Hattori, S., Matsuya, T., and Inagaki, S. (1999) J. Biol. Chem. 274, 29666-29671[Abstract/Free Full Text]
30. Carlin, R. K., Grab, D. J., Cohen, R. S., and Siekevitz, P. (1980) J. Cell Biol. 86, 831-845[Abstract]
31. Goslin, K., and Banker, G. (1991) in Culturing Nerve Cells (Goslin, K. , and Banker, G., eds) , pp. 339-370, MIT Press, Cambridge, MA
32. Inagaki, S., Takagi, H., Suzuki, K., Akai, F., and Taniguchi, N. (1991) Brain Res. 541, 354-357[CrossRef][Medline] [Order article via Infotrieve]
33. Kim, E., Cho, K. O., Rothschild, A., and Sheng, M. (1996) Neuron 17, 103-113[Medline] [Order article via Infotrieve]
34. Lue, R. A., Marfatia, S. M., Branton, D., and Chishti, A. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9818-9822[Abstract/Free Full Text]
35. Muller, B. M., Kistner, U., Veh, R. W., Cases-Langhoff, C., Becker, B., Gundelfinger, E. D., and Garner, C. C. (1995) J. Neurosci. 15, 2354-2366[Abstract]
36. Wang, L. H., Kalb, R. G., and Strittmatter, S. M. (1999) J. Biol. Chem. 274, 14137-14146[Abstract/Free Full Text]
37. Brenman, J. E., Chao, D. S., Gee, S. H., McGee, A. W., Craven, S. E., Santillano, D. R., Wu, Z., Huang, F., Xia, H., Peters, M. F., Froehner, S. C., and Bredt, D. S. (1996) Cell 84, 757-767[Medline] [Order article via Infotrieve]
38. Niethammer, M., Valtschanoff, J. G., Kapoor, T. M., Allison, D. W., Weinberg, T. M., Craig, A. M., and Sheng, M. (1998) Neuron 20, 693-707[Medline] [Order article via Infotrieve]
39. Kim, J. H., Liao, D., Lau, L. F., and Huganir, R. L. (1998) Neuron 20, 683-691[Medline] [Order article via Infotrieve]
40. Zhang, W., Vazquez, L., Apperson, M., and Kennedy, M. B. (1999) J. Neurosci. 19, 96-108[Abstract/Free Full Text]
41. Tezuka, T., Umemori, H., Akiyama, T., Nakanishi, S., and Yamamoto, T. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 435-440[Abstract/Free Full Text]
42. Migaud, M., Charlesworth, P., Dempster, M., Webster, L. C., Watabe, A. M., Makhinson, M., He, Y., Ramsay, M. F., Morris, R. G., Morrison, J. H., O'Dell, T. J., and Grant, S. G. (1998) Nature 396, 433-439[CrossRef][Medline] [Order article via Infotrieve]
43. Scheiffele, P., Fan, J., Choih, J., Fetter, R., and Serafini, T. (2000) Cell 101, 657-669[Medline] [Order article via Infotrieve]
44. Yagi, T., and Takeichi, M. (2000) Genes Dev. 14, 1169-1180[Free Full Text]
45. Ichtchenko, K., Hata, Y., Nguyen, T., Ullrich, B., Missler, M., Moomaw, C., and Sudhof, T. C. (1995) Cell 81, 435-443[Medline] [Order article via Infotrieve]
46. De Vries, L., LouX, Zhao, G., Zheng, B., and Farquhar, M. G. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 12340-12345[Abstract/Free Full Text]
47. Cai, H., and Reed, R. R. (1999) J. Neurosci. 19, 6519-6527[Abstract/Free Full Text]
48. Tamanogone, L., Artigiani, S., Chen, H., He, S., Ming, G., Song, H., Chedotal, A., Winberg, M. L., Goodman, C. S., Poo, Ml, Tessier-Lavigne, M., and Comoglio, P. M. (1999) Cell 99, 71-80[Medline] [Order article via Infotrieve]
49. Kameyama, T., Murakami, Y., Suto, F., Kawakami, A., Takagi, S., Hirata, T., and Fujisawa, H. (1996) Biochem. Biophys. Res. Commun. 226, 396-402[CrossRef][Medline] [Order article via Infotrieve]
50. Maestrini, E., Tamagnone, L., Longati, P., Cremona, O., Gulisano, M., Bione, S., Tamanini, F., Neel, B. G., Toniolo, D., and Comoglio, P. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 674-678[Abstract/Free Full Text]
51. Comeau, M. R., Johnson, R., DuBose, R. F., Petersen, M., Gearing, P., VandenBos, T., Park, L., Farrah, T., Buller, R. M., and Cohen, J. I. (1998) Immunity 8, 473-482[Medline] [Order article via Infotrieve]
52. Winberg, M. L., Noordermeer, J. N., Tamagnone, L., Comoglio, P. M., Spriggs, M. K., Tessier-Lavigne, M., and Goodman, C. S. (1998) Cell 95, 903-916[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.